SPRO Stock Overview
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
Spero Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.44|
|52 Week High||US$19.87|
|52 Week Low||US$1.43|
|1 Month Change||-74.69%|
|3 Month Change||-84.26%|
|1 Year Change||-89.44%|
|3 Year Change||-88.30%|
|5 Year Change||n/a|
|Change since IPO||-87.48%|
Recent News & Updates
|SPRO||US Biotechs||US Market|
Return vs Industry: SPRO underperformed the US Biotechs industry which returned -19.5% over the past year.
Return vs Market: SPRO underperformed the US Market which returned -8.1% over the past year.
|SPRO Average Weekly Movement||21.6%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: SPRO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.
Volatility Over Time: SPRO's weekly volatility has increased from 13% to 22% over the past year.
About the Company
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd.
Spero Therapeutics Fundamentals Summary
|SPRO fundamental statistics|
Is SPRO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SPRO income statement (TTM)|
|Cost of Revenue||US$63.09m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.14|
|Net Profit Margin||-792.03%|
How did SPRO perform over the long term?See historical performance and comparison
Is Spero Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SPRO ($1.44) is trading below our estimate of fair value ($97.5)
Significantly Below Fair Value: SPRO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SPRO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: SPRO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SPRO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SPRO is good value based on its PB Ratio (0.8x) compared to the US Biotechs industry average (1.5x).
How is Spero Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SPRO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SPRO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SPRO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SPRO's revenue (52% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: SPRO's revenue (52% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SPRO's Return on Equity is forecast to be high in 3 years time
How has Spero Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SPRO is currently unprofitable.
Growing Profit Margin: SPRO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SPRO is unprofitable, and losses have increased over the past 5 years at a rate of 21% per year.
Accelerating Growth: Unable to compare SPRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: SPRO has a negative Return on Equity (-165.13%), as it is currently unprofitable.
How is Spero Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SPRO's short term assets ($132.7M) exceed its short term liabilities ($69.2M).
Long Term Liabilities: SPRO's short term assets ($132.7M) exceed its long term liabilities ($14.2M).
Debt to Equity History and Analysis
Debt Level: SPRO is debt free.
Reducing Debt: SPRO has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SPRO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SPRO has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 18% each year.
What is Spero Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SPRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SPRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SPRO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SPRO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SPRO has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ankit Mahadevia (40 yo)
Dr. Ankit Mahadevia, MD, MBA serves as the Chief Executive Officer and President of Spero Therapeutics, LLC. Dr. Mahadevia Co-founded of Spero Therapeutics, Inc. in 2013 and has been its Chief Executive Of...
CEO Compensation Analysis
Compensation vs Market: Ankit's total compensation ($USD4.88M) is above average for companies of similar size in the US market ($USD771.97K).
Compensation vs Earnings: Ankit's compensation has increased whilst the company is unprofitable.
Experienced Management: SPRO's management team is considered experienced (2.2 years average tenure).
Experienced Board: SPRO's board of directors are considered experienced (8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.6%.
Spero Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Spero Therapeutics, Inc.
- Ticker: SPRO
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$47.263m
- Shares outstanding: 32.82m
- Website: https://sperotherapeutics.com
Number of Employees
- Spero Therapeutics, Inc.
- 675 Massachusetts Avenue
- 14th Floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/18 00:00|
|End of Day Share Price||2022/05/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.